Drug administration device

Abstract

[Problem] To prevent a member constituting a connection port from degrading due to repeated mounting / dismounting operations between a device main body and a cradle, and to increase the mountability of the device main body with respect to the cradle. [Solution] A pharmaceutical liquid administration device 100, 110 wherein: a connection port 40 has a port main body 41 which holds a cannula 50 and which engages with a cradle 30, and a rotation member 421, 424 to which a liquid feeding part 16, 19 is fitted, and which can rotate in a direction substantially parallel to a placement surface part 31a, with the central axis being the direction in which the lumen of the cannula 50 extends; and, in a state in which the liquid feeding part 16, 19 is fitted, the rotation member 421, 424 rotates along with rotational movement of a device main body 101, 111 substantially parallel to the placement surface part 31a.

Description

[Technical Field]

[0001] The present invention relates to a drug solution administration device that administers a drug solution to a target such as a living body. [Background technology]

[0002] There are known therapies in which a medicinal liquid is continuously administered into a patient's body. For example, one known treatment for diabetes patients is to continuously administer a small amount of insulin into the body. This treatment uses a portable medicinal liquid administration device that can be carried around by being fixed to the user's body or clothing. Using a portable medicinal liquid administration device, it is possible to administer medicinal liquid to the user throughout the day. An insulin pump, which administers insulin to the user, is known as this type of medicinal liquid administration device.

[0003] One of the portable drug solution administration devices proposed above is a drug solution administration device having a syringe-shaped reservoir for storing the drug solution and a plunger that is driven inside the reservoir. In the drug solution administration device, a cannula is liquid-tightly connected to a liquid delivery tube extending from the reservoir, and the cannula is placed under the skin of a user to administer the stored drug solution into the user's body.

[0004] Patent Document 1 describes a technology in which a needle member (liquid delivery needle) having a needle tube for delivering liquid is provided at the tip of the liquid delivery tube, and a rubber partition (rubber stopper) is provided at a connection port having a cannula, and the liquid delivery needle is pierced through the rubber stopper to connect the liquid delivery tube and the cannula. [Prior art documents] [Patent documents]

[0005] [Patent Document 1] European Patent No. 1951340 Summary of the Invention [Problem to be solved by the invention]

[0006] The technology described in Patent Document 1 had the following problems. A drug solution administration device such as an insulin pump comprises a device main body and a cradle that are detachable from each other. The cradle is attached and fixed to the user's skin, and the device main body is detachably attached to the cradle. The syringe (reservoir), plunger, liquid delivery tube, and liquid delivery needle described above are provided on the device main body, and the connection port described above is provided on the cradle. When the device main body is attached to the cradle, the liquid delivery needle is inserted into the rubber stopper, and the device main body is rotated (pivoted) around the puncture point to attach it to the cradle.

[0007] However, during use of a drug solution administration device, for some reason, such as when the user takes a bath or when filling the device with drug solution, the device body must be removed from the cradle and then reattached to the cradle. Therefore, the device body and the cradle are repeatedly attached and detached during use, and the liquid delivery needle is punctured and removed from the rubber stopper the same number of times. As a result, for example, the puncture hole in the rubber stopper may widen or the rubber stopper itself may be damaged, resulting in leakage of drug solution from the connection between the rubber stopper and the liquid delivery needle. In particular, the device disclosed in Patent Document 1 rotates and attaches the device body to the cradle while punctured. At this time, the liquid delivery needle twists within the rubber stopper, easily damaging the rubber stopper.

[0008] Furthermore, the device disclosed in Patent Document 1 is often worn on the abdomen or back of the user, and when the device main body is attached to the cradle, the liquid delivery needle may pierce the surface of the rubber stopper at an angle. When the liquid delivery needle pierces the rubber stopper at an angle, the puncture hole formed in the rubber stopper tends to be longer than when the needle is pierced perpendicularly to the surface of the rubber stopper, which may cause the rubber stopper to deteriorate more quickly.

[0009] At least one embodiment of the present invention has been made in consideration of the above-mentioned circumstances, and specifically, its object is to provide a drug solution administration device that can prevent deterioration of the components that make up the connection port due to repeated attachment and detachment of the device main body to the cradle, and can improve the attachment ability of the device main body to the cradle. [Means for solving the problem]

[0010] The drug solution administration device according to this embodiment includes a device main body including a reservoir for storing the drug solution, a liquid delivery drive unit for delivering the drug solution from the reservoir, a liquid delivery tube through which the drug solution delivered from the reservoir flows, and a liquid delivery unit communicating with the liquid delivery tube, a mounting surface on which a bottom surface of the device main body is placed, a connection port disposed on an upper surface of the mounting surface and holding a cannula to be inserted into a living body, and a cradle whose living body side is attached to the living body relative to the device main body, and A drug solution administration device in which a liquid part and the connection port are detachably fluidly connected, the connection port having a port main body that holds the cannula and is locked to the cradle, and a rotating member to which the liquid delivery part is attached and that is rotatable in a direction approximately parallel to the mounting surface part with the direction in which the lumen of the cannula extends as a central axis, the rotating member being configured to rotate along the device main body by rotating movement in the mounting direction approximately parallel to the mounting surface part with the liquid delivery part attached. The liquid delivery unit has a hollow cylindrical shape, the rotating member has a first communication hole that allows the drug solution introduced from the liquid delivery unit to flow, the connection port has a second communication hole that can communicate with the first communication hole and a plug that is arranged on the outer periphery of the rotating member, and the connection port rotates along the mounting surface when the device main body is mounted on the cradle by rotation in a mounting direction that is approximately parallel to the mounting direction or in a dismounting direction that is opposite to the mounting direction, and the fluid connection state with the liquid delivery unit is switched depending on the relative positional relationship between the port body and the connection port. . [Effects of the Invention]

[0011] According to at least one embodiment of the present invention, it is possible to prevent deterioration of the components that make up the connection port due to repeated attachment and detachment of the device main body to the cradle, and to improve the ease of attachment of the device main body to the cradle. [Brief explanation of the drawings]

[0012] [Figure 1] 1 is a schematic perspective view of a drug solution administration device according to a first embodiment. [Figure 2] 1 is a schematic exploded perspective view of a chemical liquid administration device according to a first embodiment. FIG. [Figure 3] 1 is a schematic partial perspective view of a drug solution administration device according to a first embodiment, as viewed from the bottom side. FIG. [Figure 4A] 3 is a schematic cross-sectional view of the drug solution administration device according to the first embodiment when the rotating member is in a closed position. FIG. [Figure 4B] 3 is a schematic cross-sectional view of the drug solution administration device according to the first embodiment when the rotating member is in an open position. FIG. [Figure 5] 5A to 5C are schematic cross-sectional views showing the operation of the drug solution administration device according to the first embodiment. [Figure 6] 5A to 5C are schematic cross-sectional views showing the operation of the drug solution administration device according to the first embodiment. [Figure 7] 5A to 5C are schematic cross-sectional views showing the operation of the drug solution administration device according to the first embodiment. [Figure 8] 5A to 5C are schematic cross-sectional views showing the operation of the drug solution administration device according to the first embodiment. [Figure 9] FIG. 10 is a schematic perspective view of a cradle of a chemical solution administration device according to a second embodiment. [Figure 10] FIG. 10 is a schematic perspective view of the drug solution administration device according to the second embodiment, as viewed from the bottom side. [Figure 11] FIG. 10 is a schematic cross-sectional view of the vicinity of a connection port of a chemical liquid administration device according to a second embodiment. [Figure 12] 10A to 10C are schematic cross-sectional views showing the operation of the drug solution administration device according to the second embodiment. [Figure 13] 10A to 10C are schematic cross-sectional views showing the operation of the drug solution administration device according to the second embodiment. DETAILED DESCRIPTION OF THE INVENTION

[0013] Hereinafter, embodiments of the present invention will be described in detail with reference to the drawings. The embodiments shown here are merely examples for embodying the technical concept of the present invention and are not intended to limit the present invention. Furthermore, all other embodiments, examples, and operational techniques that can be conceived by those skilled in the art without departing from the spirit of the present invention are included within the scope and spirit of the present invention, as well as within the scope of the claims and their equivalents.

[0014] Furthermore, for the convenience of illustration and ease of understanding, the drawings attached to this specification may be represented schematically with the scale, aspect ratio, shape, etc. appropriately changed from the actual product, but these are merely examples and do not limit the interpretation of the present invention.

[0015] Furthermore, in the following description, when ordinal numbers such as "first" and "second" are used, unless otherwise specified, they are used for convenience and do not stipulate any particular order.

[0016] For ease of explanation, the present specification uses XYZ coordinates as shown in the figures. Specifically, the "Z direction" is the vertical direction, the "X direction" is a direction perpendicular to the Z direction and parallel to the horizontal plane, and the "Y direction" is another direction perpendicular to the Z direction and parallel to the horizontal plane (direction perpendicular to the X direction). Therefore, in the drug solution administration devices 100 and 110 according to this embodiment, the Z direction coincides with the thickness direction (vertical direction) of the device, the upward direction is the direction from the surface of the living body toward the drug solution administration device 100 or 110, and the downward direction is the direction toward the surface of the living body. The X direction coincides with the longitudinal direction (front-to-back direction) along the axial direction of the device, and the Y direction coincides with the transverse direction (width direction) of the device, perpendicular to the longitudinal direction.

[0017] The medicinal liquid administration devices 100, 110 according to the present embodiment are devices for continuously administering medicinal liquid into the body of a user. Examples of medicinal liquids administered using the medicinal liquid administration devices 100, 110 include insulin, analgesics, anticancer drugs, HIV (Human Immunodeficiency Virus) drugs, iron chelating drugs, and drugs for treating pulmonary hypertension. In the present embodiment, a portable insulin pump that administers insulin into the body of a user is assumed as an example of the medicinal liquid administration device 100, 110. The medicinal liquid administration devices 100, 110, which are insulin pumps, are used by being attached to the surface of a living body. The surface of a living body is typically the surface of the user's skin. The medicinal liquid administration devices 100, 110 are attached, for example, to the user's abdomen.

[0018] [First embodiment] FIG. 1 is a schematic perspective view showing the appearance of a medicinal liquid administration device 100 according to a first embodiment, and FIG. 2 is a schematic exploded perspective view showing the main parts of the overall configuration of the medicinal liquid administration device 100. As shown in FIG.

[0019] <Configuration> As shown in Figure 1 or 2, the drug solution administration device 100 generally comprises a first main body portion 10 that holds a reservoir 12 in which the drug solution is stored, a second main body portion 20 that holds a liquid delivery drive unit 23 for delivering the drug solution in the reservoir 12 into the living body, and a cradle 30 that holds a cannula 50 and a connection port 40 and is attached to the surface of the living body.

[0020] The first main body 10 is a disposable part. The second main body 20 is a reusable part. The first main body 10 and the second main body 20 are separable from each other and can be connected to each other. The drug solution administration device 100 is made up of the device main body 101 formed by connecting the first main body 10 and the second main body 20, and the cradle 30 on which the device main body 101 is attached.

[0021] <First main body part> The first main body 10 has a housing 11, a reservoir 12, an extrusion unit 13, a liquid supply tube 14, and a power supply unit 15. The housing 11 is formed in a substantially rectangular shape in a plan view (viewed in the Z direction). The housing 11 is also a substantially rectangular parallelepiped that is open at the top.

[0022] As shown in Fig. 2, the housing 11 includes a flat bottom surface portion 11a and a side wall portion 11b that rises along the entire outer periphery of the bottom surface portion 11a. The bottom surface portion 11a is a plate portion that divides the housing 11 in the Z direction. When the device main body 101 is attached to the cradle 30, the bottom surface portion 11a is disposed opposite the cradle 30. A reservoir 12, an extrusion portion 13, a liquid delivery tube 14, and a power supply portion 15 are attached to the surface of the bottom surface portion 11a facing the second main body portion 20 (the upper surface of the bottom surface portion 11a). The bottom surface portion 11a also functions as the bottom surface portion 101a of the device main body 101 in which the second main body portion 20 is connected to the first main body portion 10.

[0023] The housing 11 includes a first storage section 11c surrounded by a bottom surface section 11a and a side wall section 11b. The first storage section 11c is a space provided on the upper surface side of the bottom surface section 11a, and contains a reservoir 12, a power supply section 15, etc. When the cover 21 of the second main body section 20 and the housing 11 are connected, the liquid delivery drive section 23 attached to the inside of the cover 21 is contained within the first storage section 11c.

[0024] The housing 11 includes a first mounting portion 11d that, when the device main body 101 is mounted on the cradle 30, engages with a second mounting portion 31c of the cradle 30, which will be described later, to maintain the mounted state between the device main body 101 and the cradle 30. The first mounting portion 11d is an engaging recess provided on the outer surface of the side wall portion 11b along the Y direction of the first main body portion 10. As shown in FIG. 2, the first mounting portion 11d is disposed on each of the two side wall portions 11b along the Y direction (i.e., the side wall portions 11b on the shorter sides) at a position facing the second mounting portion 31c when the device main body 101 is mounted on the cradle 30.

[0025] The first mounting part 11d and the second mounting part 31c function as mounting parts that stably maintain the mounted state between the device main body 101 and the cradle 30. Therefore, when the device main body 101 is mounted on the cradle 30, the medicinal solution administration device 100 can stably maintain the mounted state.

[0026] As shown in FIG. 3, the bottom surface 11a is composed of a first bottom surface 11e, a second bottom surface 11f, and a first step portion 11g. The first bottom surface 11e and the second bottom surface 11f are plate surfaces extending along the X direction. For example, the first bottom surface 11e is disposed on the bottom surface 11a in the attachment direction D1 of the device main body 101, and the second bottom surface 11f is disposed on the bottom surface 11a in the direction in which the attachment state of the device main body 101 is released (detachment direction D2). The first bottom surface 11e and the second bottom surface 11f are positioned at different levels in the thickness direction (Z direction) of the housing 11, and the second bottom surface 11f is positioned lower (closer to the living body surface) than the first bottom surface 11e. When the device main body 101 is placed on the cradle 30, the first bottom surface 11e is placed on the first placement surface 31e of the placement surface 31a. When the device main body 101 is placed on the cradle 30, the second bottom surface 11f is placed on the second placement surface 31d of the placement surface portion 31a.

[0027] Here, the "mounting direction D1" is a direction substantially parallel to the mounting surface 31a (i.e., substantially parallel to the surface of the living body) for rotating the device body 101 when mounting the device body 101 on the cradle 30 (see FIGS. 6 and 9). By rotating the device body 101 in the mounting direction D1 around the engagement position between the engagement recess 17 of the device body 101 and the connection port 40 provided on the cradle 30 (more specifically, the puncture position of the liquid delivery unit 16 relative to the stopper 43) as the center of rotation, the bottom surface 101a (bottom surface 11a) of the device body 101 can be moved above the mounting surface 31a of the cradle 30.

[0028] The "detaching direction D2" is opposite to the attachment direction D1 and is a direction substantially parallel to the placement surface 31a for rotating the device body 101 when removing the device body 101 from the cradle 30 (see FIG. 7). The device body 101 can be rotated in the detaching direction D2 around the engagement position between the engagement recess 17 of the device body 101 and the connection port 40 provided on the cradle 30, thereby moving the bottom surface 101a of the device body 101 to a position that is not above the placement surface 31a of the cradle 30. After rotating in the detaching direction D2, the device body 101 can be lifted upward to disengage the engagement recess 17 from the connection port 40 and completely detach from the cradle 30.

[0029] The first step portion 11g is provided at the boundary portion that separates the first bottom surface 11e and the second bottom surface 11f. The first step portion 11g extends longitudinally across the bottom surface portion 11a in the X direction. When the first main body portion 10 is viewed from the side (as viewed in the X direction), the first step portion 11g has a step surface that rises in a substantially vertical direction (Z direction) from the second bottom surface 11f toward the first bottom surface 11e. When the device main body 101 is attached to the cradle 30, the first step portion 11g abuts against the step surface of the second step portion 31f of the cradle 30 to restrict rotational movement of the device main body 101.

[0030] The bottom surface portion 11a only needs to have a shape complementary to the placement surface portion 31a of the cradle 30 when the device main body 101 and the cradle 30 are fully attached to each other. Therefore, the configuration of the bottom surface portion 11a is not limited to the configuration described above.

[0031] Reservoir 12 includes an outer cylinder 12a that stores a medicinal liquid to be administered to a user, and expels the medicinal liquid from outer cylinder 12a by pressing action of extrusion unit 13. Reservoir 12 has a medicinal liquid discharge port (not shown) at its tip, and one end of liquid delivery tube 14 is connected to this discharge port. The other end of liquid delivery tube 14 is connected to liquid delivery unit 16 from the first storage unit 11c side of housing 11. Reservoir 12 has gear 12b near its end. Gear 12b rotates by receiving a driving force from liquid delivery drive unit 23. An end of the rotation shaft of gear 12b is engaged with feed screw 12c. Feed screw 12c is provided so as to be movable in the X direction. Reservoir 12 rotates gear 23b and gear 12b by driving liquid delivery drive unit 23, and moves extrusion unit 13 in the X direction as feed screw 12c rotates in accordance with the rotation of gear 12b. The liquid medicine in the reservoir 12 is delivered to the liquid delivery tube 14 according to the amount of pressure applied by the extrusion part 13, which moves with the rotation of the feed screw 12c. The liquid delivery tube 14 is detachably fluidly connected (a connected state in which the liquid medicine can flow) to a connection port 40, which will be described later, via the liquid delivery part 16.

[0032] The reservoir 12 is not limited to a syringe, but may be any other container capable of storing a liquid medicine, such as a soft bag, etc. The reservoir 12 may be any container capable of discharging the liquid medicine by the extrusion portion 13.

[0033] The power supply unit 15 supplies the driving power required to drive the medicinal solution administration device 100. The power supply unit 15 is composed of a battery that serves as a power source for driving, for example, the liquid delivery drive unit 23, and a battery box that houses the battery. The power supply unit 15 is connected to electrodes (not shown) on the circuit board 22. The power supply unit 15 may be disposed inside the lid 21 as a component of the second main body unit 20.

[0034] The liquid delivery unit 16 has a hollow cylindrical shape with a liquid delivery hole 16a formed at its tip. The base end of the liquid delivery unit 16 is connected to the liquid delivery tube 14, and the tip is attached to a connection port 40 provided on the cradle 30. The liquid delivery hole 16a is formed so as to penetrate the liquid delivery unit 16 along the central axis of the liquid delivery unit 16. As shown in FIG. 3, the liquid delivery unit 16 is disposed inside an engagement recess 17 provided on the bottom surface 11a of the first main body unit 10 so as not to protrude beyond the bottom surface 11a (second bottom surface 11f).

[0035] A first engagement portion 16b that engages with a second engagement portion 421e of the rotating member 421, which will be described later, is provided at the tip of the liquid delivery unit 16. As an example, the first engagement portion 16b is configured as a notched groove that extends axially from the tip of the liquid delivery unit 16 toward the base end. When the device main body 101 is temporarily attached to the cradle 30, the first engagement portion 16b is inserted into the connection port 40 and engages with the second engagement portion 421e. When the liquid delivery unit 16 is attached to the rotating member 421, the first engagement portion 16b engages with the second engagement portion 421e, and transmits the rotational force caused by the rotational movement of the device main body 101 in the attachment direction D1 to the rotating member 421 via the second engagement portion 421e.

[0036] The engagement recess 17 is recessed in the thickness direction of the housing 11 from the bottom surface 11a (more specifically, the second bottom surface 11f) of the first main body 10. The inner peripheral shape and inner dimensions of the engagement recess 17 are set according to the outer shape and outer dimensions of the connection port 40 with which it is to be engaged. When the device main body 101 is attached to the cradle 30, the engagement recess 17 engages to cover the outer periphery of the connection port 40. The engagement recess 17 is disposed on the first bottom surface 11e at a position facing the connection port 40 when the device main body 101 is attached to the cradle 30. The liquid delivery unit 16 is disposed in approximately the center of the engagement recess 17. Note that, for the purpose of further stabilizing the attachment operation, the inner peripheral surface of the engagement recess 17 may be provided with a structure such as a screw or a notch that rotates and engages with the outer peripheral surface of the connection port 40.

[0037] <Second main body> The second main body 20 has a cover 21, a circuit board 22, and a liquid delivery drive unit 23, and is connected to the first main body 10. The second main body 20 is a portion where the electronic control functions of the medicinal liquid administration device 100 are collectively arranged. The second main body 20 is configured by accommodating electronic control function components such as the circuit board 22 and the liquid delivery drive unit 23 inside the cover 21.

[0038] The lid 21 is configured to be detachable from the housing 11 of the first main body 10. The upper surface of the lid 21 forms the top surface of the medicinal solution administration device 100. Electronic control function components such as a circuit board 22 and a liquid delivery drive unit 23 are attached to the lower surface side of the lid 21.

[0039] The liquid delivery drive unit 23 includes a motor 23a and a gear 23b. The motor 23a is a drive source for moving the extruding unit 13 in a predetermined direction to deliver the liquid medicine from the reservoir 12. The gear 23b is made up of multiple gears, and the final gear meshes with the gear 12b. As a result, the driving force (rotational force) of the motor 23a is transmitted to the gear 12b via the gear 23b to drive the extruding unit 13.

[0040] The second main body 20 also includes a liquid delivery amount detection unit 24 that can detect the amount of liquid medicine delivered based on the rotation speed of a motor 23a, such as an encoder, a communication unit 25 that is an interface for enabling communication with the outside, and a control unit 26 that is configured by a known microcomputer including a CPU, ROM, RAM, etc. The communication unit 25 and the liquid delivery drive unit 23 operate based on a predetermined program under the control of the control unit 26.

[0041] Cradle The cradle 30 has a cradle body 31 and a connection port 40. The cradle body 31 has a mounting surface 31a. The connection port 40 is attached to the upper surface of the cradle body 31 (mounting surface 31a).

[0042] An adhesive portion 31b is provided on the underside of the cradle main body 31. A portion of the adhesive portion 31b protrudes outward more than the placement surface portion 31a, and is a portion for attaching the cradle 30 to the surface of a living body (the user's skin). The placement surface portion 31a is formed in a substantially rectangular shape in a plan view.

[0043] When the device main body 101 is attached to the cradle 30, the bottom surface 101a of the device main body 101 (the bottom surface 11a of the first main body 10) is placed on the placing surface 31a. A second attachment portion 31c is provided on a short side (side along the Y direction) of the placing surface 31a and is attached to the first attachment portion 11d of the first main body 10. The second attachment portion 31c has a hook-shaped engagement protrusion on its tip side that fits with the first attachment portion 11d, and is provided upright in the thickness direction (Z direction) relative to each short side of the placing surface 31a. The second attachment portion 31c engages with the first attachment portion 11d when the device main body 101 is attached to the cradle 30.

[0044] The placement surface portion 31a is composed of a first placement surface 31e, a second placement surface 31d, and a second step portion 31f. The first placement surface 31e and the second placement surface 31d are plate surfaces extending along the X direction. The first placement surface 31e is located on the placement surface portion 31a in the attachment direction D1, and the second placement surface 31d is located on the placement surface portion 31a in the removal direction D2. As shown in FIG. 2, the first placement surface 31e and the second placement surface 31d are located at different levels in the thickness direction (Z direction) of the cradle main body 31, and the first placement surface 31e is located higher than the second placement surface 31d. When the device main body 101 is placed on the cradle 30, the first bottom surface 11e of the bottom surface portion 11a is placed on the first placement surface 31e. The second bottom surface 11f of the bottom surface portion 11a is placed on the second placement surface 31d when the device main body 101 is placed on the cradle 30. In this way, the cradle main body 31 has a plurality of surface portions with different thicknesses from the surface of the living body.

[0045] The second step portion 31f is provided at the boundary portion that separates the first mounting surface 31e and the second mounting surface 31d. The second step portion 31f extends longitudinally across the cradle main body 31 in the X direction. When the cradle 30 is viewed from the side, the second step portion 31f has a step surface that rises in a substantially vertical direction (Z direction) from the second mounting surface 31d toward the first mounting surface 31e. When the device main body 101 is attached to the cradle 30, the second step portion 31f abuts against the first step portion 11g and functions as an abutment surface that restricts rotational movement of the device main body 101 in the attachment direction D1.

[0046] The mounting surface 31a only needs to have a shape complementary to the bottom surface 101a of the device main body 101 (the bottom surface 11a of the first main body 10) when the device main body 101 and the cradle 30 are completely attached to each other. The bottom surface 11a is formed so as to complementarily mate with the mounting surface 31a of the cradle 30 and become one unit when the device main body 101 and the cradle 30 are completely attached to each other. That is, the bottom surface 11a and the mounting surface 31a are connected to each other, so that their shapes complement each other across at least one axial direction of the medicinal solution administration device 100. Therefore, the configuration of the bottom surface 11a is not limited to the configuration described above. More specifically, when the device main body 101 and the cradle 30 are completely attached to each other, the mounting surface 31a has an abutment surface that restricts movement of the device main body 101 in the attachment direction, and the device main body 101 has a surface on the bottom surface 11a that faces the abutment surface. It is sufficient that the bottom surface portion 11a and the mounting surface portion 31a have complementary structures at least in part, and preferably, in a plan view of the medicinal solution administration device 100, the complementary shapes are arranged closer to the D1 side than the engagement recess 17 and the connection port 40, or on the corner side facing the corner where the engagement recess 17 and the connection port 40 are arranged. In addition to the abutment surface that restricts the movement of the device body 101, the bottom surface portion 11a and the mounting surface portion 31a can be appropriately provided with structures such as switches and notches that are necessary for the function and manufacture of the medicinal solution administration device 100.

[0047] In the medicinal liquid administration device 100, the bottom surface 11a and the placing surface 31a have complementary shapes. Therefore, when the device main body 101 of the medicinal liquid administration device 100 is attached to the cradle 30, the attachment position and the movement direction are easy to grasp, improving wearability. This is particularly useful because the medicinal liquid administration device 100 is often attached to the abdomen or back of the user. Note that, from the viewpoint of improving wearability, it is preferable that the bottom surface 11a and the placing surface 31a of the medicinal liquid administration device 100 have complementary shapes, but they do not necessarily have to have complementary shapes.

[0048] <Connection port> 4A or 4B, the connection port 40 is provided on the upper surface of the mounting surface 31a of the cradle 30. The connection port 40 includes a port main body 41, a connection portion 42, a plug body 43, and a holding portion 44.

[0049] When the device main body 101 is attached to the cradle 30, the connection port 40 is fluidly connected to the liquid delivery unit 16 via the connection part 42. The connection port 40 is arranged on the mounting surface part 31a of the cradle 30 at a position where the device main body 101 can rotate when the device main body 101 is temporarily attached to the cradle 30. Specifically, the connection port 40 is arranged near a corner of the mounting surface part 31a of the cradle 30. The connection port 40 connects to the engagement recess 17 of the device main body 101.

[0050] The port body 41 is the base of the connection port 40 and is engaged with the mounting surface 31a of the cradle 30. The port body 41 has a storage recess 411 at its top for storing the rotating member 421 and the stopper 43, and is disposed on the mounting surface 31a of the cradle 30. The storage recess 411 is a concave space having an opening 412 approximately in the center of its bottom. The storage recess 411 communicates with the holding portion 44 and cannula 50 located below it and the opening 412. A side groove 413 is provided on the inner circumferential surface of the port body 41, and a flow path is formed between the outer surface of the stopper 43 and the inner circumferential surface of the port body 41 (opening 412).

[0051] A holding portion 44 is provided at the bottom of the port body 41 of the connection port 40 to hold the proximal end of a cannula 50 that is placed in a living body and delivers a medicinal solution into the living body. The cannula 50 protrudes from the holding portion 44 toward the user's body, with at least the tip portion being placed in the living body. The cannula 50 is made of a resin material such as polyurethane, nylon, or ethylene-tetrafluoroethylene copolymer (ETFE). A puncture tool (not shown) holds the connection port 40, which holds the puncture needle and cannula 50, and inserts the puncture needle and cannula 50 into the living body through the cradle opening 31g. Simultaneously or subsequently, the connection port 40 is locked to the cradle 30 by a known locking means. After the puncture needle is removed from the cradle 30, the puncture tool is removed from the cradle 30 along with the puncture needle and discarded.

[0052] Holding portion 44 is formed in a funnel shape to guide the medicinal liquid that flows in when first communication hole 421d of rotating member 421 and second communication hole 431 of stopper 43 are in a communication state, to cannula 50. Therefore, the medicinal liquid that flows into opening 412 and holding portion 44 through first communication hole 421d, second communication hole 431, and side groove 413 flows along the inner surface of holding portion 44 and is introduced into the living body via cannula 50.

[0053] Connection part 42 is disposed at a position facing liquid delivery part 16 on the upper part of port main body 41. When device main body 101 is mounted on cradle 30, connection part 42 and port main body 41 function as an introduction port that introduces the medicinal liquid delivered through liquid delivery part 16 into connection port 40. Connection part 42 also functions as a puncture port that is inserted with a puncture needle (not shown) when cannula 50 is placed in a living body.

[0054] The connection portion 42 is composed of a rotary member 421 , a seal portion 422 , and a housing portion 423 .

[0055] The rotating member 421 is held in the storage recess 411 so as to be rotatable in a direction substantially parallel to the mounting surface 31a, with the direction in which the lumen of the cannula 50 extends as its central axis. The rotating member 421 is housed in a recess of the stopper 43 on the port main body 41. The rotating member 421 is a cylindrical member with a hollow center and different inner diameters, and has a large-diameter portion 421a and a small-diameter portion 421b located below the large-diameter portion 421a. Between the large-diameter portion 421a and the small-diameter portion 421b, i.e., at the portion where the inner diameter transitions on the inner circumferential surface of the large-diameter portion 421a, a step 421c is provided that protrudes from the lower end of the large-diameter portion 421a toward the inside of the rotating member 421 (toward the central axis of the connection portion 42 in the Z direction). Step portion 421c is continuous with the inner circumferential surface of large diameter portion 421a and the inner circumferential surface of small diameter portion 421b, and the inner diameter of rotating member 421 transitions and decreases at step portion 421c. Seal portion 422 is placed between the inner surface of housing 423 and step portion 421c.

[0056] A first communication hole 421d is provided on the inner circumferential surface of the small-diameter portion 421b of the rotating member 421. When the rotating member 421 is in the open position, the first communication hole 421d communicates with the second communication hole 431 of the stopper 43. When the first communication hole 421d and the second communication hole 431 are in communication, the medicinal liquid delivered from the liquid delivery section 16 can flow through the side groove 413 to the holding section 44. When the rotating member 421 is in the closed position, the first communication hole 421d abuts against the side wall 433 of the stopper 43, blocking communication with the outside. This blocks the flow of the medicinal liquid and the like from the first communication hole 421d toward the cannula 50 in the connection port 40.

[0057] The aforementioned "closed position" is a movement position of the rotating member 421 for closing the first communication hole 421d with the stopper 43 and interrupting the fluid connection between the liquid supply unit 16 and the connection port 40 when the device main body 101 is not attached to the cradle 30. The "open position" is a movement position of the rotating member 421 for opening the first communication hole 421d (i.e., communicating with the second communication hole 431) and fluidly connecting the liquid supply unit 16 and the connection port 40 when the device main body 101 is attached to the cradle 30. The closed position and the open position can be switched depending on the position of the device main body 101 with respect to the cradle 30.

[0058] A second engagement portion 421e that engages with the first engagement portion 16b of the liquid delivery unit 16 is provided on the inner circumferential surface of the small diameter portion 421b of the rotating member 421. The second engagement portion 421e is, for example, a ridge portion extending in the axial direction on the inner circumferential surface of the small diameter portion 421b. The second engagement portion 421e engages with the first engagement portion 16b when the device main body 101 is temporarily attached to the cradle 30. At this time, the distal end surface of the liquid delivery unit 16 may be configured not to abut against the stopper 43 in order to ensure a flow path of sufficient size for the flow rate of the drug solution. Alternatively, an additional slit or notch may be provided at the distal end of the liquid delivery unit 16. The second engagement portion 421e engages with the first engagement portion 16b when the liquid delivery unit 16 is attached to the rotating member 421, and the rotational force caused by the rotational movement of the device main body 101 in the attachment direction D1 is transmitted to the rotating member 421. This allows the rotating member 421 to rotate along with the rotational movement of the device body 101. The second engaging portion 421e can be appropriately designed to match the shape of the first engaging portion 16b so that it can engage with the first engaging portion 16b.

[0059] On the inner circumferential surface of the rotating member 421, the positions of the first communication hole 421d and the second engagement portion 421e are set based on the amount of movement (rotational movement distance) of the device main body 101 when the device main body 101 and the cradle 30 are rotated in the attachment direction D1 from a temporary attachment state to complete attachment. Therefore, the first communication hole 421d can be provided at a position where it abuts against and is closed by the side wall 433 of the plug 43 when the rotating member 421 is in the closed position. In addition, the first communication hole 421d can be provided at a position where it communicates with the second communication hole 431 when the rotating member 421 moves from the closed position to the open position.

[0060] The rotating member 421 is located in the closed position when the device body 101 is not attached to the cradle 30. As shown in FIG. 4B , the first engagement portion 16b engages with the second engagement portion 421e when the device body 101 is temporarily attached to the cradle 30. With the first engagement portion 16b and the second engagement portion 421e engaged, the rotating member 421 rotates from the closed position to the open position as the device body 101 rotates in the attachment direction D1. As a result, the first communication hole 421d and the second communication hole 431 coincide with each other and communicate with each other, so that the liquid delivery unit 16 and the connection port 40 are fluidly connected.

[0061] Furthermore, when the device body 101 is detached from the cradle 30, the rotating member 421 rotates from the open position to the closed position in accordance with the rotational movement of the device body 101 in the attachment / detachment direction D2. As a result, the first communication hole 421d is closed by the side wall 433 of the plug 43, and the fluid connection between the liquid delivery section 16 and the connection port 40 is cut off.

[0062] Seal portion 422 comes into close contact with the outer peripheral surface of the tip end of liquid delivery portion 16 attached in attachment hole 423a of housing portion 423. Therefore, seal portion 422 can improve the liquid-tightness in the connected state between liquid delivery portion 16 and housing portion 423. Seal portion 422 can be an O-ring made of a flexible material such as a rubber material or a thermoplastic elastomer.

[0063] Housing portion 423 is a lid-like member having a top surface and a peripheral surface and an open bottom, and is attached to the top of port main body 41 so as to cover rotating member 421. An attachment hole 423a that communicates with the inside of housing portion 423 is provided in the upper surface (top surface) of housing portion 423. Liquid delivery portion 16 is inserted into attachment hole 423a when device main body 101 is temporarily attached to cradle 30. Housing portion 423 may be fixedly attached to port main body 41, or may be attached so as to be rotatable in accordance with the rotational movement of device main body 101. Attachment hole 423a is designed so that a puncture needle for puncturing and inserting cannula 50 can be inserted therethrough.

[0064] The stopper 43 has a recessed opening at the top to accommodate the rotating member 421, a sidewall 433 surrounding the opening, a bottom 434, and a flange 432 on the outer periphery of the opening, forming a cylindrical shape with a bottom. The stopper 43 is accommodated in the accommodation recess 411 with the rotating member 421 accommodated above it. As shown in FIGS. 4A and 4B , when the stopper 43 is accommodated in the accommodation recess 411, the flange 432 is sandwiched between the port main body 41 and the housing portion 423. This fixes (holds) the stopper 43 in position within the accommodation recess 411, sealing the proximal end of the side groove 413. The bottom 434 is adapted to be penetrated by a puncture needle for puncturing and inserting the cannula 50.

[0065] A second communication hole 431 is provided in a side wall 433 of the plug 43. The second communication hole 431 is disposed at a position that allows communication with the first communication hole 421d when the rotary member 421 is in the open position.

[0066] Stopper 43 can be made of a flexible and resealable material. Examples of flexible materials include various rubber materials such as silicone rubber and natural rubber, and various thermoplastic elastomers such as polyurethane, polyester, polyamide, olefin, and styrene. That is, after the puncture needle that has penetrated stopper 43 is removed from the top opening of stopper 43, stopper 43 reseals connection portion 42 to block communication with the outside.

[0067] The medicinal solution administration device 100 according to the first embodiment is configured so that, with an engagement recess 17 provided on the device body 101 engaged with a connection port 40 of the cradle 30, the device body 101 is rotated and moved substantially parallel to the surface of a living body relative to the cradle 30 to be attached to or separated from the cradle 30. In the medicinal solution administration device 100 configured as described above, when the liquid delivery unit 16 is attached to the connection unit 42, the first engagement portion 16b and the second engagement portion 421e engage with each other. When the device body 101 is rotated in the attachment direction D1, the rotating member 421 rotates in conjunction with the rotation of the device body 101, and rotates from a closed position to an open position, thereby connecting the first communication hole 421d and the second communication hole 431 to each other. In other words, the medicinal liquid administration device 100 is configured to be able to switch the fluid connection state between the liquid delivery section 16 and the connection port 40 depending on the relative positional relationship of the rotating member 421, which rotates as the device body 101 rotates, with respect to the port body 41.

[0068] In conventional technology, the liquid delivery needle repeatedly punctures and removes the rubber stopper provided in the connection port. As a result, with the conventional technology, as the number of times the device body and the cradle are attached and detached increases, for example, the puncture hole in the rubber stopper widens or the rubber stopper itself becomes damaged, potentially resulting in leakage of the liquid medicine from the connection point between the rubber stopper and the liquid delivery needle. If the liquid medicine leaks during use of the liquid medicine administration device, especially when the administration amount is small, the patient tends to be slow to notice the leak, which is undesirable. In contrast, the liquid medicine administration device 100 of the first embodiment is configured such that the hollow tubular liquid delivery unit 16 is attached to the attachment hole 423a of the housing 423, and the fluid connection state between the liquid delivery unit 16 and the connection port 40 can be switched depending on the relative position of the rotating member 421 with respect to the port body 41. Therefore, the liquid medicine administration device 100 can achieve improved durability compared to conventional devices. Furthermore, in the drug solution administration device 100, the liquid delivery section 16 and the connection port 40 are fluidly connected only when the rotating member 421 is in the open position, so communication with the outside can be blocked when the device main body 101 is not attached to the cradle 30.

[0069] Furthermore, in the medicinal solution administration device 100, the rotating member 421 is configured to rotate along with the device body 101 by rotating the device body 101 in the mounting direction D1 that is substantially parallel to the mounting surface 31a when the liquid delivery unit 16 is attached. Therefore, when the user attaches the device body 101 to the cradle 30, the rotating member 421 serves as the center of rotation and guides the rotation direction of the device body 101, allowing the user to stably perform the attachment operation.

[0070] <Operation> Next, the operation of mounting the device main body 101 on the cradle 30 in the chemical solution administration device 100 according to the first embodiment will be described with reference to FIGS.

[0071] As a preliminary step before using the drug solution administration device 100, the user attaches the cradle 30 to the surface of the living body and places the cannula 50 inside the living body. When placing the cannula 50, the user attaches the adhesive portion 31b of the cradle 30 to the skin and uses a puncture tool (not shown) to insert the cannula 50 together with the connection portion 42 into the living body. The cannula 50 is inserted into the living body using a puncture needle. With the cannula 50 left inside the living body, the user removes the puncture needle and the puncture tool (not shown) used to insert the puncture needle from the cradle 30.

[0072] Next, the user assembles the device main body 101 by connecting the second main body 20 to the first main body 10. The user lowers the assembled device main body 101 in the Z direction relative to the cradle 30 so as to engage the engagement recess 17 with the connection port 40. As a result, the device main body 101 is temporarily attached with the engagement recess 17 of the device main body 101 engaged with the connection port 40, as shown in FIG. 5. Furthermore, with the device main body 101 and the cradle 30 attached, the liquid delivery unit 16 is inserted into the attachment hole 423a of the housing 423, and the first engagement portion 16b engages with the second engagement portion 421e. The rotating member 421 is located in the closed position before the device main body 101 rotates in the attachment direction D1.

[0073] As shown in Fig. 6, the user rotates the device body 101 in the mounting direction D1, and then engages the first mounting portion 11d with the second mounting portion 31c. At this time, the user rotates the device body 101 to a position where the first step portion 11g of the bottom surface portion 101a of the device body 101 abuts against the second step portion 31f of the cradle 30. This brings the medicinal solution administration device 100 into a fully mounted state, as shown in Fig. 6.

[0074] 6, when the first engaging portion 16b and the second engaging portion 421e are engaged, the rotating member 421 rotates from the closed position to the open position in response to rotation of the device body 101 in the mounting direction D1. This connects the first communicating hole 421d and the second communicating hole 431, establishing a liquid medicine flow path (the side groove 413, which is a flow path connecting to the cannula 50 within the connection port 40) that communicates with the liquid medicine delivery unit 16. The liquid medicine delivery unit 16 and the connection port 40 are fluidly connected, enabling liquid medicine administration by the liquid medicine administration device 100. In this state, if the user activates the liquid medicine administration device 100, the liquid medicine delivery drive unit 23 is driven at a predetermined timing to cause the liquid medicine stored in the reservoir 12 to flow from the liquid medicine delivery unit 16 to the port body 41 via the liquid medicine delivery tube 14. The liquid medicine that flows into the port body 41 upon activation of the liquid medicine administration device 100 is introduced into the living body through the cannula 50.

[0075] When removing the device body 101 from the cradle 30 while using the drug solution administration device 100, the user disengages the first mounting portion 11d from the second mounting portion 31c, as shown in FIG. 7, and then rotates the device body 101 in the removal direction D2 around the engagement position between the engagement recess 17 and the connection port 40. As a result, a portion of the bottom surface 101a of the device body 101 separates from the mounting surface 31a of the cradle 30. Furthermore, as the device body 101 rotates in the removal direction D2, the rotating member 421 rotates from the open position to the closed position. As a result, the first communication hole 421d is closed by the side wall 433 of the stopper 43, and the fluid connection between the liquid delivery unit 16 and the connection port 40 is interrupted. Thereafter, the user moves the device body 101 upward, as shown in FIG. 8. As a result, the device body 101 is completely removed from the cradle 30. At this time, since the rotary member 421 is in the closed position, the first communication hole 421d is in a closed state, and communication between the connection port 40 and the outside is blocked.

[0076] [Second embodiment] Next, a drug solution administration device 110 according to a second embodiment will be described with reference to Figures 9 to 13. In the second embodiment, components having the same functions as those in the first embodiment described above are denoted by the same reference numerals, and detailed description thereof will be omitted. Configurations, members, and usage methods that are not specifically mentioned may be similar to those in the above-described embodiment.

[0077] The second embodiment described below shows a configuration in which the shape of the engagement recess 17a provided on the bottom surface 111a of the device body 111 and the shape of the connection port 40 are changed.

[0078] <Configuration> In the medicinal solution administration device 110 according to the second embodiment, the rotating member 424 is rotatably attached to the upper outer peripheral surface of the port main body 41 of the connection port 40. The rotating member 424 engages with the engaging recess 17a when the device main body 111 is temporarily attached to the cradle 30. Furthermore, the medicinal solution administration device 110 according to the second embodiment includes a needle-shaped liquid delivery unit 19 instead of the hollow cylindrical liquid delivery unit 16.

[0079] The liquid delivery unit 19 is a needle member having a hollow needle tube and a sharp puncture tip. The base end of the liquid delivery unit 19 is connected to the liquid delivery tube 14, and the tip puncture tip penetrates and punctures the stopper 43 of the connection port 40 provided in the cradle 30. As shown in FIG. 10 , the liquid delivery unit 19 is disposed inside the engagement recess 17a provided in the bottom surface 11a of the first main body unit 10 so as not to protrude from the engagement recess 17a.

[0080] The engagement recess 17a is recessed in the thickness direction of the housing 11 relative to the bottom surface 11a (more specifically, the first bottom surface 11e) of the first main body portion 10. The inner peripheral surface 171 of the engagement recess 17a has an uneven shape in which convex and concave portions formed in radial directions from the axial center (extension direction of the liquid delivery unit 19) are alternately arranged along the circumferential direction. The inner peripheral surface 171 of the engagement recess 17a engages with the outer peripheral surface 424d of the rotating member 424. The liquid delivery unit 19 is arranged in approximately the center of the engagement recess 17a.

[0081] The port body 41 is engaged with the mounting surface 31a of the cradle 30. The port body 41 holds the rotating member 424 so that the rotating member 424 can rotate about its axis. A seal 425 is disposed between the port body 41 and the rotating member 424. The seal 425 seals the gap between the rotating member 424 and the port body 41, thereby sealing the port body 41. As with the seal 422, an O-ring made of a flexible, sealing material such as a rubber material or a thermoplastic elastomer can be used for the seal 425.

[0082] Rotating member 424 has a hollow cylindrical shape with a storage portion 424a provided inside, and has a hollow shaft portion 424c extending below storage portion 424a.

[0083] The storage portion 424a has a concave shape with an opening 424b in the approximate center of its bottom that communicates with the inner cavity of the shaft portion 424c, and stores the plug 43. The opening 424b of the storage portion 424a communicates with the holding portion 44 via the inner cavity of the shaft portion 424c. The rotating member 424 includes a hollow cylindrical shaft portion 424c that extends downward from the bottom of the storage portion 424a. The shaft portion 424c is stored in a storage recess 411 provided in the base of the port main body 41.

[0084] The outer peripheral surface 424d of the rotating member 424 has an uneven shape in which convex and concave portions formed in radial directions from the axial center are alternately arranged along the circumferential direction. The outer peripheral surface 424d of the rotating member 424 engages with the inner peripheral surface 171 of the engagement recess 17a. That is, the inner peripheral shape of the engagement recess 17a and the outer peripheral shape of the connection port 40 have complementary shapes. Note that the inner peripheral surface 171 of the engagement recess 17a and the outer peripheral surface 424d of the rotating member 424 only need to have complementary shapes, so the shape of the convex and concave portions and the spacing between them in the circumferential direction are not particularly limited.

[0085] The rotating member 424 is attached to the port main body 41 so as to be rotatable in an attachment direction D1 and an attachment / detachment direction D2 (see FIG. 9 ). When the device main body 111 is rotationally moved in the attachment direction D1 after the device main body 111 has been temporarily attached to the cradle 30, the rotating member 424 rotates while remaining engaged with the engagement recess 17a in association with this movement. More specifically, with the liquid delivery unit 19 punctured, the rotating member 424 rotates while remaining engaged with the engagement recess 17a, with the center of rotation being the engagement position between the engagement recess 17a and the rotating member 424 (more specifically, the puncture position of the liquid delivery unit 19 relative to the stopper 43). Furthermore, when the device main body 111 is rotationally moved in the attachment / detachment direction D2 to remove the device main body 111 from the cradle 30, the rotating member 424 rotates while remaining engaged with the engagement recess 17a in association with this movement.

[0086] In the second embodiment, both the puncture needle and the liquid delivery section 19 are punctured and removed from the stopper 43. After the puncture needle that has penetrated the stopper 43 is removed, the stopper 43 seals the connection section 42 to block communication with the outside. Furthermore, after the liquid delivery section 19 that has penetrated the stopper 43 is removed, the stopper 43 seals the connection section 42 to block communication with the outside.

[0087] Similar to the drug solution administration device 100 according to the first embodiment, the drug solution administration device 110 according to the second embodiment is configured such that the device body 111 is attached or separated by rotating it relative to the cradle 30 with the engagement recess 17a provided on the device body 111 engaged with the connection port 40 of the cradle 30. In the drug solution administration device 110 configured in this manner, the rotating member 424 is rotatably attached to the port body 41, and the stopper 43 is disposed inside the rotating member 424. When the device body 111 is temporarily attached to the cradle 30, the drug solution administration device 110 is attached by piercing the liquid delivery section 19 into the stopper 43. After the device main body 111 of the drug solution administration device 110 is temporarily attached to the cradle 30, the device main body 111 is rotated in the attachment direction D1, and as this movement occurs, the device main body 111 rotates while engaged with the engagement recess 17a, with the engagement position between the engagement recess 17a and the rotating member 424 (the puncture position of the liquid delivery section 19 relative to the stopper body 43) as the center of rotation.

[0088] Therefore, when the device main body 111 and the cradle 30 are attached to each other, the device main body 111 can be rotated while the liquid delivery unit 19 remains punctured into the stopper 43, without the puncturing position of the liquid delivery unit 19 shifting in the vertical or horizontal direction. Therefore, the drug solution administration device 110 can reduce damage to the stopper 43 by the liquid delivery unit 19. Furthermore, when the device main body 111 is attached to the cradle 30, the liquid delivery unit 19 punctures the stopper 43 with the engagement recess 17a guided by the rotating member 424. This makes it difficult for the liquid delivery unit 19 to puncture the stopper 43 at scattered locations, thereby reducing deterioration of the stopper 43 due to breakage. Furthermore, when the user mounts the device main body 111 on the cradle 30, the rotating member 424 serves as the center of rotation to guide the rotation direction of the device main body 111, so the liquid delivery section 19 does not move during the rotation operation, allowing the user to perform the mounting operation stably.

[0089] <Operation> Next, the operation of mounting the device body 111 on the cradle 30 in the chemical solution administration device 110 according to the second embodiment will be described with reference to FIGS.

[0090] As a preliminary step before using the drug solution administration device 110, the user attaches the cradle 30 to the surface of the living body and places the cannula 50 inside the living body. When placing the cannula 50, the user attaches the adhesive part 31b of the cradle 30 to the skin, and inserts the puncture needle and the cannula 50 through the cradle opening 31g to insert only the cannula 50 into the living body. With the cannula 50 left inside the living body, the user removes the puncture needle and the puncture tool (not shown) used to insert the puncture needle from the connection part 42 and the cradle 30.

[0091] Next, the user assembles the device main body 111 by connecting the second main body 20 to the first main body 10. The user lowers the assembled device main body 111 in the Z direction relative to the cradle 30 so as to engage the engagement recess 17a with the rotating member 424 of the connection port 40. As a result, the device main body 111 is temporarily attached with the engagement recess 17a of the device main body 111 and the rotating member 424 of the connection port 40 engaged, as shown in FIG. 11 . At this time, the liquid delivery unit 19 is attached by penetrating through the stopper 43. As a result, the connection port 40 forms a liquid medicine flow path (a flow path connected to the cannula 50 within the connection port 40) that communicates with the liquid delivery unit 19, enabling the liquid medicine administration device 110 to administer the liquid medicine. In other words, the connection port 40 is in a state of fluid connection with the liquid delivery unit 19. However, the device main body 111 has not yet been completely attached to the cradle 30.

[0092] 12, the user rotates device body 111 in mounting direction D1 to engage first mounting portion 11d with second mounting portion 31c. At this time, the user rotates device body 111 to a position where first step portion 11g of bottom surface portion 111a of device body 111 abuts against second step portion 31f of cradle 30. Furthermore, while engaged with engagement recess 17a, rotating member 424 rotates along with engagement recess 17a, with the engagement position between engagement recess 17a and rotating member 424 as the rotation center. At this time, liquid delivery unit 19 is in a state of being punctured by stopper 43, but the puncturing posture at the time of puncturing is maintained by rotating member 424 along with engagement recess 17a.

[0093] The user rotates the device main body 111 in the mounting direction D1, and then engages the first mounting portion 11d with the second mounting portion 31c. As a result, the device main body 111 is completely placed on the cradle 30, and the mounting of the medicinal liquid administration device 110 is completed, as shown in FIG. 13. With the device main body 111 mounted on the cradle 30, the user can activate the medicinal liquid administration device 110, which will drive the liquid delivery drive unit 23 at a predetermined timing to cause the medicinal liquid stored in the reservoir 12 to flow from the liquid delivery unit 19 through the liquid delivery tube 14 and into the port main body 41. The medicinal liquid that flows into the port main body 41 upon activation of the medicinal liquid administration device 110 is introduced into the living body through the cannula 50.

[0094] When removing the device body 111 from the cradle 30 while using the medical solution administration device 110, the user disengages the first mounting portion 11d from the second mounting portion 31c, and then rotates the device body 111 in the removal direction D2 around the engagement position of the engagement recess 17a and the connection port 40 as the rotation center. As a result, a portion of the bottom surface 111a of the device body 111 separates from the mounting surface 31a of the cradle 30. The rotating member 424 also rotates as the device body 111 rotates in the removal direction D2. The user then moves the device body 111 upward. As a result, the device body 111 is completely removed from the cradle 30. After removing the liquid delivery portion 19 that has penetrated the stopper 43, the connection port 40 seals the connection portion 42, thereby blocking communication with the outside.

[0095] [Action and effect] As described above, the drug solution administration devices 100, 110 of this embodiment comprise device main bodies 101, 111 each having a reservoir 12 for storing the drug solution, a liquid delivery drive unit 23 for delivering the drug solution from the reservoir 12, a liquid delivery tube 14 through which the drug solution delivered from the reservoir 12 flows, and liquid delivery units 16, 19 communicating with the liquid delivery tube 14; a support surface 31a on which the bottom surfaces 101a, 111a (bottom surface 11a) of the device main bodies 101, 111 are placed; a cradle disposed on the upper surface of the support surface 31a and having a connection port 40 for holding a cannula 50 to be inserted into a living body, the living body side of which is attached to the living body relative to the device main bodies 101, 111; and the liquid delivery units 16, 19 and the connection port 40 are detachably fluidly connected. In the drug solution administration devices 100, 110 having such a configuration, the connection port 40 has a port main body 41 that holds the cannula 50 and is engaged with the cradle 30, and rotating members 421, 424 to which the liquid delivery units 16, 19 are attached and which can rotate in a direction approximately parallel to the mounting surface 31a with the direction in which the inner cavity of the cannula 50 extends as the central axis, and the rotating members 421, 424 are configured to rotate the device main body 101, 111 by a rotational movement approximately parallel to the mounting surface 31a when the liquid delivery units 16, 19 are attached.

[0096] With the medicinal solution administration devices 100, 110 configured as described above, when a user attaches the device main body 101, 111 to the cradle 30, the rotational direction of the device main body 101, 111 is guided around the rotating members 421, 424 as the rotation center, allowing for stable attachment and preventing the attachment posture of the liquid delivery units 16, 19 from shifting vertically or horizontally. For example, in a configuration such as the medicinal solution administration device 110 according to the second embodiment, in which a needle member having a needle tube is used as the liquid delivery unit 19 and punctures and connects it to a stopper 43 provided in the connection port 40, the puncture position of the liquid delivery unit 19 relative to the stopper 43 is less likely to shift during rotation of the device main body 111. Therefore, in the medicinal solution administration device 110, the widening of the puncture hole in the stopper 43 is suppressed, and damage and deterioration of the sealing ability of the stopper 43 caused by puncture wounds oriented in a different direction relative to the thickness direction of the stopper 43 due to repeated puncturing and removal are reduced.

[0097] In addition, in the medicinal liquid administration device 100 of the first embodiment, the liquid delivery section 16 is hollow cylindrical, the rotating member 421 has a first communication hole 421d through which the medicinal liquid introduced from the liquid delivery section 16 flows, the connection port 40 has a stopper 43 which has a second communication hole 431 which can communicate with the first communication hole 421d and is arranged on the outer periphery of the rotating member 421, and the connection port 40 rotates along the mounting surface 31a when the device main body 101 is mounted on the cradle 30 by rotation in an approximately parallel mounting direction D1 or in an unmounting direction D2 opposite to the mounting direction D1, and the fluid connection state with the liquid delivery section 16 can be switched depending on the relative positional relationship with the connection port 40.

[0098] The medicinal liquid administration device 100 configured in this manner is configured such that the hollow cylindrical liquid delivery unit 16 is attached to the connection port 40 (rotating member 421), and the fluid connection state between the liquid delivery unit 16 and the connection port 40 can be switched depending on the relative position of the rotating member 421 with respect to the port main body 41. Because the liquid delivery unit 16 does not use a needle, the medicinal liquid administration device 100 can avoid the problem of medicinal liquid leaking from the connection port due to damage and deterioration of the rubber stopper. Furthermore, the user can switch the fluid connection state between the liquid delivery unit 16 and the connection port 40 simply by rotating the device main body 101 in the attachment direction D1 or the detachment direction D2. In this way, flow path switching can be achieved in conjunction with the connection operation of the device main body 101.

[0099] Furthermore, in the drug solution administration device 100 of the first embodiment, the rotating member 421 is rotatably attached to the port body 41 between a blocking position that blocks the first communication hole 421d and an opening position that opens the first communication hole 421d, and is configured to move from the blocking position to the opening position as the device body 101 rotates in the mounting direction D1 with the liquid delivery section 16 attached, thereby connecting the first communication hole 421d and the second communication hole 431 to fluidly connect the liquid delivery section 16 and the connection port 40.

[0100] According to the medicinal solution administration device 100 configured in this manner, the user can simply attach the liquid delivery unit 16 to the rotating member 421 and rotate it in the attachment direction D1 of the device body 101, causing the rotating member 421 to rotate and move from the closed position to the open position, thereby connecting the first communication hole 421d and the second communication hole 431 to each other and fluidly connecting the liquid delivery unit 16 and the connection port 40. Furthermore, in the medicinal solution administration device 100, the liquid delivery unit 16 and the connection port 40 are fluidly connected only when the rotating member 421 is in the open position, and therefore communication with the outside can be blocked when the device body 101 is not attached to the cradle 30.

[0101] Furthermore, in the drug solution administration device 100 of the first embodiment, the liquid delivery unit 16 has a first engagement portion 16b at its tip, the rotating member 421 has a second engagement portion 421e that can engage with the first engagement portion 16b, and the first engagement portion 16b engages with the second engagement portion 421e when the liquid delivery unit 16 is attached to the rotating member 421, so that the rotational force caused by the rotational movement of the device main body 101 in the attachment direction D1 is transmitted to the rotating member 421 via the second engagement portion 421e.

[0102] According to the medicinal solution administration device 100 configured in this manner, the first engagement portion 16b and the second engagement portion 421e are engaged with each other, so that the rotational force caused by the rotational movement of the device body 101 can be transmitted to the rotation member 421. Therefore, the rotation member 421 can be rotated from the closed position to the open position by the mounting operation when mounting the device body 101 on the cradle 30. Therefore, when the device body 101 is mounted on the cradle 30, the medicinal solution administration device 100 can easily switch the fluid connection state between the liquid delivery unit 16 and the connection port 40.

[0103] Furthermore, in the drug solution administration devices 100, 110 according to this embodiment, the rotating members 421, 424 may be configured such that the seal portions 422, 43 that come into close contact with the outer peripheral surfaces of the attached liquid delivery units 16, 19 are disposed inside the rotating members 421, 424.

[0104] According to the thus configured medicinal liquid administration device 100, 110, the sealing portions 422, 43 are in close contact with the outer periphery of the attached liquid delivery portion 16, 19, thereby improving the liquid-tightness when the liquid delivery portion 16, 19 is connected to the rotating member 421.

[0105] In the drug solution administration device 110 according to the second embodiment, the rotation member 421 may be configured to be provided on the outer circumferential surface 424d of the connection port 40.

[0106] According to the medicinal liquid administration device 110 configured in this manner, the device main body 111 can be stably attached to the cradle 30 while maintaining the fluid connection between the liquid delivery section 19 and the stopper body 43 .

[0107] Furthermore, in the drug solution administration device 110 of the second embodiment, the liquid delivery unit 19 consists of a needle member having a needle tube, the device main body 111 has the liquid delivery unit 19 provided inside and has an engagement recess 17a on the bottom surface portion 111a (11a) that can engage with the rotating member 424, the rotating member 424 has a stopper body 43 through which the liquid delivery unit 19 is inserted, and when the liquid delivery unit 19 is inserted into the stopper body 43, it may be configured to rotate along the mounting surface portion 31a of the device main body 111 by rotational movement in an approximately parallel mounting direction D1 or in an unmounting direction D2 opposite to the mounting direction D1.

[0108] According to the medicinal solution administration device 110 configured in this manner, when the device main body 111 is attached to the cradle 30, even if the liquid delivery unit 19 is needle-shaped, it can be rotated while puncturing the stopper 43 without the puncturing posture of the liquid delivery unit 19 being displaced in the vertical or horizontal direction. Therefore, the medicinal solution administration device 110 can reduce damage to the stopper 43 by the liquid delivery unit 19.

[0109] Furthermore, in the drug solution administration devices 100, 110 according to this embodiment, the device bodies 101, 111 may be configured to have a first mounting part 11d on the side surface, and the cradle 30 may be configured to have a second mounting part 31c that engages with the first mounting part 11d.

[0110] According to the thus configured medicinal liquid administration devices 100, 110, when the device main body 101, 111 is attached to the cradle 30, the first attachment part 11d and the second attachment part 31c are engaged with each other to maintain a stable attachment state, so that the two parts can be used safely without separating during use.

[0111] This application is based on Japanese Patent Application No. 2021-050938, filed on March 25, 2021, the disclosure of which is incorporated by reference in its entirety. [Explanation of symbols]

[0112] 10 first body portion, 11 housing (11a bottom portion, 11d first mounting portion), 12 reservoirs, 14. Fluid delivery tube, 16 hollow cylindrical liquid delivery portion (16a liquid delivery hole, 16b first engagement portion), 17 17a engagement recess, 19. A liquid delivery unit having a needle tube; 20 second body portion, 23 liquid delivery drive unit (23a motor, 23b gear), 30 cradles, 31 cradle body (31a mounting surface portion, 31c second mounting portion), 40 connection ports, 42 connection portion (41 port body, 421, 424 rotating member, 421d first communication hole, 421e second engagement portion, 422 seal portion, 424d outer circumferential surface), 43 Plug body (431 second communication hole), 50 cannulae, 100, 110 Drug administration device; 101, 111 device main body (101a, 111a bottom part), D1 mounting direction, D2 Uninstallation direction.

Claims

1. a device body including a reservoir for storing a liquid medicine, a liquid delivery drive unit for delivering the liquid medicine from the reservoir, a liquid delivery tube through which the liquid medicine delivered from the reservoir flows, and a liquid delivery unit communicating with the liquid delivery tube; a cradle including a mounting surface on which the bottom surface of the device body is placed, and a connection port arranged on the upper surface of the mounting surface and holding a cannula to be inserted into a living body, the living body side of the device body being attached to the living body; A medicinal liquid administration device in which the liquid delivery unit and the connection port are detachably fluidly connected, The connection port is a port body that holds the cannula and is locked to the cradle; a rotating member to which the liquid delivery unit is attached and which is rotatable in a direction substantially parallel to the placement surface unit with a central axis in a direction in which the lumen of the cannula extends, the rotating member is configured to rotate along the mounting surface portion of the device body by a rotational movement in a mounting direction that is substantially parallel to the mounting surface portion, with the liquid delivery unit attached to the rotating member; The liquid delivery section has a hollow cylindrical shape, the rotating member includes a first communication hole through which the chemical solution introduced from the liquid delivery section flows; the connection port includes a plug having a second communication hole that can communicate with the first communication hole and that is disposed on the outer circumferential side of the rotary member; A drug solution administration device in which the connection port rotates along the mounting surface when the device main body is mounted on the cradle, in a mounting direction that is approximately parallel to the mounting direction, or in a dismounting direction that is opposite to the mounting direction, and the fluid connection state with the liquid delivery section is switched depending on the relative positional relationship between the port main body and the connection port.

2. the rotating member is attached to the port body so as to be rotatable between a closing position at which the first communication hole is closed and an opening position at which the first communication hole is opened, The drug solution administration device of claim 1, wherein when the liquid delivery unit is attached, it rotates with the device body in the attachment direction, moving from the closed position to the open position, thereby connecting the first communication hole and the second communication hole to fluidly connect the liquid delivery unit and the connection port.

3. the liquid delivery unit has a first engagement portion at a tip thereof, the rotating member includes a second engaging portion engageable with the first engaging portion, The drug solution administration device of claim 1 or 2, wherein the first engagement portion engages with the second engagement portion when the liquid delivery portion is attached to the rotating member, and is configured to transmit rotational force due to rotational movement of the device main body in the attachment direction to the rotating member via the second engagement portion.

4. The drug solution administration device according to any one of claims 1 to 3, wherein the rotating member has a seal portion disposed inside the rotating member that is in close contact with an outer peripheral surface of the attached liquid delivery portion.

5. The drug solution administration device according to claim 1 , wherein the rotating member is provided on an outer peripheral surface of the connection port.

6. the liquid delivery unit is made of a needle member having a needle tube, the device body has the liquid delivery section provided inside and an engaging recess that can engage with the rotating member provided on the bottom surface thereof; The drug solution administration device of claim 5, wherein the rotating member has a stopper body through which the liquid delivery section is inserted, and is configured to rotate along with the rotation of the device main body in the mounting direction when the liquid delivery section is attached to the stopper body.

7. the device body has a first mounting portion on a side surface thereof, The drug solution administration device according to any one of claims 1 to 6, wherein the cradle includes a second mounting portion that engages with the first mounting portion.

Images